Supplemental Information

Inventory of Supplementary Materials

Supplementary figures and legends:

Figure S1, related to Figure 1. Centrosome amplification does not promote DNA damage or cytokinesis failure.

Figure S2, related to Figure 2. There is no Plk4 overexpression or centrosome amplification in the brain of doxycycline-treated Plk4^{Dox} mice.

Figure S3, related to Figure 2. Centrosome amplification leads to progressive hair loss.

Figure S4, related to Figure 3 and Figure 4. Centrosome amplification leads to aneuploidy in the spleen of aged mice.


Figure S5, related to Figure 5. Transient Plk4 overexpression triggers spontaneous tumor development.


Supplementary Figure Plk4 ab #1 Plk4 ab #3 mRNA levels over control 2.5 Fold change in Plk4 centrosomal PIK4 2.0 Fold change in 1.5 1.0 0.5 0-0.0 DAPI γ-Tubulin Plk4 3 5 7 Days on dox 14 0 0 3 5 7 Days on dox 0 Ε Centrosome number 120 80 % of cells with >5 γ H2AX foci 100 100-> 2 centrosomes 60 % cells with 80 % of cells 75 60 40 50 40 20 n.s. 25 20 Dox 0_ 0 0 3 5 7 Days on dox 0 14 Doxo. 14 0 Plk4^{Dox} rtTA Plk4 Days on dox Untreated % of cells with DNA >4N 15 10 +Dox Untreated n.s. % binuclear cells 8 +Dox 10 Cell # 6 5 0 1 2 3 4 3 5 7 Days on Dox 14 2N 4N 6N 8N Days on Dox K Centrosome number p53 KO p53 KO +Dox *** % of cells
with >2 centrosomes 125 100 % of cells 75 50 25 0-Dox: 0 7 Z 14 3

3

7 Days

Supplementary Figure 2







Normal

. System

Supplementary Figure 4



Supplementary Figure 5



Supplemental Figure Legends

- **Figure S1, related to Figure 1.** Centrosome amplification does not promote DNA damage or cytokinesis failure
- (A) Quantification of the level of Plk4 mRNA in Plk4^{Dox} MEFs at different times after doxycycline treatment. Data are means ±SEM (N = 3, performed in triplicate).
- (B) Quantification of the level of centrosomal Plk4 at different times after doxycycline treatment. Data are means ±SEM from two different Plk4 antibodies (Plk4 ab #1 and #3) (N = 3, >150 centrosomes per experiment).
- (C) Representative immunofluorescent images of centrosomal Plk4 in Plk4^{Dox} MEFs.
- (D) Quantification of centrosome number in Plk4 Dox MEFs at different times after doxycycline treatment. Data are means ±SEM (N = 3, >150 cells per experiment).
- (E) Quantification of the level of centrosome amplification in Plk4-EYFP, rtTA and Plk4^{Dox} MEFs at two days after doxycycline addition. Data are means ±SEM (N = 3, >150 cells per experiment).
- (F) Quantification of DNA damage foci in Plk4 Dox MEFs at different times after doxycycline treatment. Doxorubicin treatment (Doxo.) is shown as a control. Data are means \pm SEM (N = 3, >150 cells per experiment).
- (G) Quantification of the fraction of binuclear Plk4 Dox MEFs at different times after doxycycline treatment. Data are means ±SEM (N = 3, >135 cells per experiment).
- (H) Quantification of the fraction of Plk4 $^{\text{Dox}}$ MEFs with >4N DNA content at different times after doxycycline treatment. Data are means ±SEM (N = 3, 10,000 cells per experiment).
- (I) Representative flow cytometry profiles show cell cycle analysis in Plk4^{Dox} MEFs.

- (J) Quantification of the level of centrosome amplification in Plk4 Dox ; p53 $^{-/-}$ MEFs at different times after doxycycline addition. Data are means ±SEM (N = 3, >150 cells per experiment).
- (K) Quantification of centrosome number in Plk4^{Dox}; p53^{-/-} MEFs at different times after doxycycline treatment. Data are means \pm SEM (N = 3, >150 cells per experiment). *P < 0.05, **P < 0.01, ***P < 0.005 and NS (not significant) indicates P > 0.05; two-tailed Student's t-test.

Figure S2, related to Figure 2. There is no Plk4 overexpression or centrosome amplification in the brain of doxycycline-treated Plk4^{Dox} mice

- (A) Graph showing the fold increase in Plk4 mRNA in tissues from Plk4 Dox mice treated with doxycycline for 1 month. Data are means \pm SEM (N = 3, performed in triplicate).
- (B) Quantification of the level of centrosomal Plk4 in tissues from Plk4 Dox mice treated with doxycycline for 1 month. Representative immunofluorescent images show centrosomal Plk4 in tissue sections. Data are means ±SEM (N = 3). Scale bar represents 10 μ m.
- (C) Quantification of the level of centrosome amplification in tissues from Plk4 Dox mice treated with doxycycline for 8 months. Data are means ±SEM (N = 4).
- (D) Quantification of centrosome number in tissues from Plk4^{Dox} mice treated with doxycycline for 1 month. Data are means \pm SEM (N = \geq 4).
- (E) Images of tissue sections taken from Histone H2B-mCherry;rtTA mice treated with doxycycline for 1 month. The Histone H2B-mCherry expression construct was integrated at the same location as the Plk4-EYFP transgene. This reporter showed

widespread doxycycline-inducible expression, but was undetectable in the brain. Scale bar represents 200 µm.

*P < 0.05, **P < 0.01, ***P < 0.005 and NS (not significant) indicates P > 0.05; two-tailed Student's t-test.

Figure S3, related to Figure 2. Centrosome amplification leads to progressive hair loss.

- (A) Quantification of cortex thickness measured in four-month old control or Plk4 Dox animals treated with doxycycline for 3 months (N = 3). Images show the cerebral cortex in control and Plk4 Dox mice. Scale bar represents 200 μ m.
- (B) Images show hair loss in eight-month old Plk4^{Dox} animals fed doxycycline chronically from one week of age.
- (C) Pathology report from eight-month old $Plk4^{Dox}$ animals fed doxycycline chronically from one week of age. Tissues analyzed by a veterinary pathologist (N = 4 for control and $Plk4^{Dox}$ mice).
- (D) Images show hematoxylin and eosin stained tissue sections from eight-month old control and Plk4 Dox mice fed doxycycline chronically from one week of age. Scale bars represent 200 μ m.

Figure S4, related to Figure 3 and Figure 4. Centrosome amplification leads to aneuploidy in the spleen of aged mice

- (A and B) Fraction of splenocytes with the indicated number of chromosomes. Cells were derived from control and $Plk4^{Dox}$ mice treated with doxycycline for either 1 or 8 months. Data are means \pm SEM (N = 3, 50 cells per experiment).
- (C) Quantification of the fraction of Plk4 Dox or control splenocytes with >4N DNA content at different times after doxycycline treatment. Data are means ±SEM (N = 3, 10,000 cells per experiment). Representative flow cytometry profiles show cell cycle analysis in Plk4 Dox and control splenocytes.
- (D) Quantification of the level of Plk4 mRNA in APC $^{Min/+}$; Plk4 Dox MEFs at different times after doxycycline treatment. Data are means ±SEM (N = 3, performed in triplicate).
- (E) Graph showing the fold increase in cell number for $APC^{Min/+}$; $Plk4^{Dox}$ MEFs grown in the presence and absence of doxycycline. Data are means $\pm SEM$ (N = 5, performed in triplicate).
- (F) Graph showing the APC⁺ to APC^{Min} PCR ratios generated from intestinal adenomas (Polyp) and normal intestine (Int.) from APC^{Min/+} and APC^{Min/+}; Plk4^{Dox} mice. The mean APC⁺/APC^{Min} value for adenomas from APC^{Min} and APC^{Min}; Plk4^{Dox} mice is reduced compared to normal tissue from these animals, indicating partial loss of the APC⁺ allele. Data are means \pm SEM (N = \geq 2, performed in duplicate).

P < 0.01, *P < 0.001 and n.s. (not significant) indicates P > 0.05; two-tailed Student's t-test.

Figure S5, related to Figure 5. Transient Plk4 overexpression triggers spontaneous tumor development

(A) Quantification of centrosome number in tumors that arise in Plk4^{Dox} mice chronically

fed doxycycline. Data are means ±SEM. (N = ≥4).

- (B) Quantification of the fraction of cleaved caspase 3 positive cells in tumors from $Plk4^{Dox}$ and $p53^{-/-}$ mice. Data are means $\pm SEM$. (N = ≤ 4 , with each data point representing a single tumor).
- (C) Graph showing the expression level of p53 target genes in tumors formed in Plk4^{Dox} and p53^{-/-} mice.
- (D) Quantification of the level of centrosome amplification in tissues from 16-18 month old Plk4^{Dox} mice treated with doxycycline for 1 month. Data are means \pm SEM (N = \geq 3).
- (E) Kaplan-Meier survival analysis of Plk4^{Dox} and control (C57BL/6J) mice fed doxycycline at 1 month of age for one month. *P* value was calculated using the Log-rank test.
- (F) Quantification of the level of centrosome amplification in tumors from Plk4^{Dox} mice fed doxycycline for one month. Each point represents a single tumor and horizontal lines represent the mean.
- (G) Low-coverage whole-genome sequencing (WGS) plots for a B-cell Lymphoma derived from Plk4^{Dox} mice fed doxycycline for one month.
- (H-I) Low-coverage whole-genome sequencing plots of two T-Cell Lymphomas, and four Squamous Cell Carcinomas (SCC) derived from Plk4^{Dox} mice chronically treated with doxycycline.